# The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients

> **NCT05527444** · PHASE4 · UNKNOWN · sponsor: **Qilu Hospital of Shandong University** · enrollment: 100 (estimated)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Secukinumab 150 mg/ml
- **DRUG:** Adalimumab Ab
- **DRUG:** NSAID
- **DRUG:** Thalidomide Pill

## Key facts

- **NCT ID:** NCT05527444
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-15
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05527444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05527444, "The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05527444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*